Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA notice about NIH’s website transition and terminology update appears on the page, and the footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.5%

- Check28 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1, reflecting a minor site-version update.SummaryDifference0.1%

- Check35 days agoChange DetectedThis snapshot shows the study record history with multiple version entries, but no additions or deletions are recorded in this dataset.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded a new revision entry v3.7.0 to the history, indicating a page/system update. The prior revision v3.6.6 is removed from the deletions, updating the record of changes shown on the history page.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision entry v3.6.6 was added to the study record history, indicating an updated version of the record, and the previous revision v3.6.5 was removed from the visible list.SummaryDifference0.1%

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.